Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Apr 12, 2021 10:16am
99 Views
Post# 32976827

RE:RE:Annual meeting

RE:RE:Annual meeting

Irrational market behaviour?? I believe the irrational market behaviour has been all over this company for a long time, as mentioned earlier the SP had no problem to react negatively when there are negative news and now even to positive news.
Who is responsible to take care of it if not the company?
50% increase from a multi year depressed level after getting the go a head for NASH phase 3 and staring phase 1 oncology in timely fashion, growing sales encouraging preclinical data doesn't represent a fair valuation at all imo.
Any other biotech company would be screaming loud and clear these great results so the market start hearing it, again today's news only stays relevant tomorrow and beyond when it is repeatedly communicated.
 


qwerty22 wrote:

The stock is up 50% in two months. The eposters are mostly strong affirmation of stuff we already knew, they've had a really good preclinical program but it's just preclinical. There are limitations to this type of data. It strikes me people are EXPECTING irrational market behaviour and then blaming the company when it doesn't arrive.

 

Bucknelly21 wrote: I am prepared to vote... we have 922 followers on st, about 12 regular posters here, poor marketing, and a massive failure to capitalize on all the accomplishments. This in the second largest bull market in history. What good does it do if no one sees anything you are achieving and your not shouting out about it everyday to the market. Bottom line in my opinion is while the board has always taken care of itself come proxy time but being able to take care of shareholders long and short they continue to fail on making adequate changes in the way they market the opportunity. You can say ir or whatever you'd like but the board is responsible for making sure that those changes are made. Just like wino said he hoped wouldn't happen is happening every time there is significant news. The tree fell again and no one heard it. 

 

 



<< Previous
Bullboard Posts
Next >>